Brief: Nanobiotix Says Authorities Okay Reclassification of JNJ-1900 To Medicinal Product
08/07/2025 05:43
July 8 (Reuters) - Nanobiotix SA NANOB.PA: THE COMPANY SAID ON MONDAY THAT HEALTH AUTHORITIES IN MAJOR EUROPEAN COUNTRIES HAVE ACCEPTED THE RECLASSIFICATION OF JNJ-1900 (NBTXR3) FROM A MEDICAL DEVICE TO A MEDICINAL PRODUCT MEDICINAL PRODUCT CLASSIFICATION SUPPORTS UNIFIED GLOBAL REGULATORY CLASSIFICATION, FACILITATING FUTURE GLOBAL STRATEGIES AND FILINGS NEW COMPOSITION OF MATTER PATENT FOR JNJ-1900 (NBTXR3) HAS BEEN FILED Source text Further company coverage: NANOB.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering